EUVIMEDScopri EUVIMED
Systematische ÜbersichtOpen access · CC BY 4.0

Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review

Ai Kuzumi, Takashi Yamashita, Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Shinichi Sato, Ayumi Yoshizaki

Experimental Dermatology · 2024

DOI: 10.1111/exd.15064 ↗

At a glance

Systematische Übersicht in Experimental Dermatology, 2024. Written by Ai Kuzumi and 5 co-authors. Institution: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan. Major MEDLINE topics: Cannabinoids, Autoimmune Diseases. Cited 11 times so far (Crossref); 123 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

In recent years, the medical use of cannabinoids has attracted growing attention worldwide. In particular, anti‐inflammatory properties of cannabinoids led to their emergence as potential therapeutic options for autoimmune and inflammatory disorders. Recent studies have also shown that cannabinoid receptors are widely expressed and have endogenous ligands in the skin, suggesting that the skin has its own endocannabinoid system. The aim of this review is to discuss the potential therapeutic effects of cannabinoids in autoimmune and inflammatory skin diseases. Following an overview of cannabinoids and the endocannabinoid system, we describe the cellular and molecular mechanisms of cannabinoids in skin health and disease. We then review the clinical studies of cannabinoids in autoimmune and inflammatory skin diseases including systemic sclerosis (SSc), dermatomyositis (DM), psoriasis (Pso) and atopic dermatitis (AD). A primary literature search was conducted in July 2023, using PubMed and Web of Science. A total of 15 articles were included after excluding reviews, non‐human studies and in vitro studies from 389 non‐duplicated articles. Available evidence suggests that cannabinoids may be beneficial for SSc, DM, Pso and AD. However, further studies, ideally randomized controlled trials, are needed to further evaluate the use of cannabinoids in autoimmune and inflammatory skin diseases.

Subjects

MeSH terms (MEDLINE)

CannabinoidsAutoimmune DiseasesHumansSkin DiseasesScleroderma, SystemicAnti-Inflammatory AgentsEndocannabinoidsDermatomyositisSkinPsoriasis

Author keywords

atopic dermatitisauto‐immune diseasepsoriasis

Substances

CannabinoidsAnti-Inflammatory AgentsEndocannabinoids

Authors and institutions

  • Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Department of Clinical Cannabinoid Research, University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Cite

APA

Kuzumi, A., Yamashita, T., Fukasawa, T., Yoshizaki-Ogawa, A., Sato, S., & Yoshizaki, A. (2024). Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review. Experimental Dermatology. https://doi.org/10.1111/exd.15064

Vancouver

Kuzumi A, Yamashita T, Fukasawa T, Yoshizaki-Ogawa A, Sato S, Yoshizaki A. Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review. Experimental Dermatology. 2024. doi:10.1111/exd.15064

BibTeX
@article{Kuzumi2024,
  author = {Kuzumi, Ai and Yamashita, Takashi and Fukasawa, Takemichi and Yoshizaki-Ogawa, Asako and Sato, Shinichi and Yoshizaki, Ayumi},
  title = {Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review},
  journal = {Experimental Dermatology},
  year = {2024},
  doi = {10.1111/exd.15064}
}
Start for free →